Evidence map›Paper›PMID 19071179›Full record

ArticleVaccine2009

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

M L Tondella, G M Carlone, N Messonnier, C P Quinn, B D Meade, D L Burns, J D Cherry, N Guiso, E L Hewlett, K M Edwards and 12 more

Open access · greenAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011
    Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Evaluation of Commercial Assays for Single-Point Diagnosis of Pertussis in the US.Journal of the Pediatric Infectious Diseases Society · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Comparison of commercially available immunoblot assays measuring IgG and IgA antibodies to Bordetella pertussis antigens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2011
    Article
  19. Pertussis serodiagnosis in Belgium from 1990 to 2009.Clinical and vaccine immunology : CVI · 2011
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 9 countries.

M L TondellaCenters for Disease Control and Prevention, Atlanta, GA 30333, USA. mtondella@cdc.gov
G M Carlone
N Messonnier
C P Quinn
B D Meade
D L Burns
J D Cherry
N Guiso
E L Hewlett
K M Edwards
D Xing
A Giammanco
C H Wirsing von König
L Han
L Hueston
J B Robbins
M Powell
C M Mink
J T Poolman
S W Hildreth
F Lynn
A Morris
Centers for Disease Control and Prevention · USNational Institutes of Health · USCenter for Biologics Evaluation and Research · USDalhousie University · CAGlaxoSmithKline (Belgium) · BEGovernment of the United Kingdom · GBHarbor–UCLA Medical Center · USHeat Biologics (United States) · USInstitut für Hygiene und Umwelt · DEInstitut Pasteur · FRMassachusetts Department of Public Health · USNational Institute for Biological Standards and Control · GBSanofi (United States) · USUniversity of California, Los Angeles · USUniversity of Palermo · ITUniversity of Virginia · USVanderbilt University Medical Center · USWestmead Institute for Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consensus opinion on existing gaps in understanding standardization of pertussis assays used for serodiagnosis and vaccine evaluation; and (4) to search for a multicenter process for addressing these priority gaps. Presentations and discussions by content experts addressed these objectives. A prioritized list of action items to improve standardization and harmonization of pertussis assays was identified during a group discussion at the end of the meeting. The major items included: (1) to identify a group that will organize, prepare, maintain, and distribute proficiency panels and key reagents such as reference and control sera; (2) to encourage the development and identification of one or more reference laboratories that can serve as an anchor and resource for other laboratories; (3) to define a performance-based assay method that can serve as a reference point for evaluating laboratory differences; (4) to develop guidance on quality of other reagents, e.g., pertussis toxin and other antigens, and methods to demonstrate their suitability; (5) to establish an international working group to harmonize the criteria to evaluate the results obtained on reference and proficiency panel sera; (6) to create an inventory to determine the amount of appropriate and well-characterized sera that are available globally to be used as bridging reagents for vaccine licensure; and (7) to seek specific guidance from regulatory authorities regarding the expectations and requirements for the licensure of new multicomponent pertussis vaccines.

Indexed as

Bordetella pertussisCenters for Disease Control and Prevention, U.S.Clinical Laboratory TechniquesHumansUnited StatesWhooping Cough

Identifiers

PMID19071179
PMCPMC7131739
OpenAlexW2068832719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.